Clinical Trial Update: X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update for X-396 (Ensartinib) capsules in ALK-positive non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Lung Cancer Non-small Cell

Drugs mentioned

• X-396

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Lung Cancer, Nonsmall Cell, Brain Metastases | Phase 2 | Status: UNKNOWN